ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
ORIC Pharmaceuticals reported Q2 2026 financial results, noting initiation of the Himalayas-1 global Phase 3 trial for rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC) and a clinical collaboration with Bayer. The company anticipates key program updates in the second half of 2026 for both rinzimetostat and enozertinib, target…